Kallikrein‑Kinin System Disorder (KKS Disorder)

Overview

The kallikrein‑kinin system (KKS) is a network of enzymes and proteins that helps regulate blood pressure, inflammation, pain, and vascular permeability. When this system becomes over‑active or dysfunctional, it can produce a group of conditions collectively referred to as Kallikrein‑Kinin System Disorder. The disorder is most commonly seen as hereditary or acquired forms of angio‑edema, but it can also be implicated in certain forms of hypertension, hereditary renal disease and rare inflammatory syndromes.

• Who it affects: Both sexes and all ages can be affected. Hereditary forms usually appear in childhood or adolescence, while acquired forms often develop in adults.
• Prevalence:
  • Hereditary angio‑edema (HAE) caused by C1‑inhibitor deficiency, which is the best‑known KKS‑related disorder, occurs in 1–5 per 100,000 people worldwide.
  • Acquired angio‑edema linked to auto‑antibodies against C1‑inhibitor or ACE‑inhibitor use is less common, estimated at 0.1–0.5 per 100,000 per year.
  • Rare KKS‑related hypertension (e.g., due to plasma kallikrein excess) affects < 0.01 % of the general population.

Symptoms

Because the KKS influences several physiological pathways, symptom patterns can be diverse. The most frequent presentation is episodic swelling (angio‑edema), but other signs may appear depending on the specific defect.

Typical angio‑edema symptoms

• Subcutaneous swelling: Soft, non‑itchy, non‑urticarial swelling of the face, lips, tongue, throat, hands or feet. Swelling can reach several centimeters in diameter.
• Gastrointestinal attacks: Abdominal pain, nausea, vomiting, diarrhoea, and sometimes intestinal wall edema that can mimic an acute abdomen.
• Upper airway involvement: Swelling of the larynx or pharynx can cause voice change, difficulty swallowing, or a feeling of throat tightness.
• Onset and duration: Attacks typically develop over 2‑12 hours and resolve spontaneously within 48‑72 hours without scarring.

Additional possible manifestations

• Hypotension or hypertension: Excess bradykinin can cause vasodilation leading to low blood pressure; conversely, plasma‑kallikrein excess may raise blood pressure.
• Painful muscle cramps or arthralgia: Due to increased vascular permeability and inflammatory mediators.
• Skin flushing or erythema: Often accompanies attacks but is not itchy.
• Renal involvement: Rarely, kallikrein‑mediated glomerular injury can cause proteinuria or hematuria.

Causes and Risk Factors

KKS disorder can be hereditary (genetic mutations) or acquired (auto‑immune or drug‑induced). The underlying problem is usually either a deficiency of an inhibitor (most commonly C1‑esterase inhibitor, C1‑INH) or uncontrolled activation of plasma/tissue kallikrein.

Hereditary causes

• HAE type I: Quantitative deficiency of C1‑INH due to SERPING1 gene mutation (≈85 % of cases).
• HAE type II: Dysfunctional C1‑INH with normal levels but reduced activity (≈15 % of cases).
• HAE with normal C1‑INH (HAE‑nC1INH): Mutations in genes such as FXII, PLG, ANGPT1, KNG1 that increase kallikrein activation.

Acquired causes

• Auto‑antibodies against C1‑INH (often associated with lymphoproliferative disorders or autoimmune disease).
• Use of angiotensin‑converting‑enzyme (ACE) inhibitors, which block bradykinin degradation.
• Severe infections, surgical trauma, or estrogen‑containing oral contraceptives that amplify kallikrein activity.

Risk factors

• Family history of hereditary angio‑edema.
• Female sex – estrogen can exacerbate attacks, especially in HAE‑nC1INH.
• Use of ACE inhibitors or neprilysin inhibitors (e.g., sacubitril).
• Underlying lymphoproliferative disease or autoimmune conditions (for acquired forms).

Diagnosis

Accurate diagnosis requires a combination of clinical history, laboratory testing, and sometimes genetic analysis.

Clinical evaluation

• Detailed description of attack frequency, triggers, and symptom distribution.
• Family pedigree to assess hereditary patterns.
• Exclusion of allergic angio‑edema (presence of urticaria, response to antihistamines).

Laboratory tests

1. C1‑INH quantitative level: Low in HAE type I.
2. C1‑INH functional assay: Low activity in both type I and II; normal in HAE‑nC1INH.
3. Complement C4 level: Usually low during attacks and inter‑attack periods in hereditary forms.
4. Plasma kallikrein activity or bradykinin assay: Mostly research tools; not routinely available.
5. Auto‑antibody testing: For acquired HAE, detects anti‑C1‑INH antibodies.

Genetic testing

Sequencing of the SERPING1 gene and, when indicated, FXII, PLG, KNG1, ANGPT1 is recommended for patients with normal C1‑INH levels but a clinical picture suggestive of HAE‑nC1INH. Genetic counseling is advised before testing.

Imaging (when needed)

• CT or MRI of the neck for airway assessment during a severe attack.
• Abdominal imaging if gastrointestinal attacks are recurrent and diagnosis is uncertain.

Treatment Options

Treatment strategies aim to prevent attacks, shorten their duration, and manage emergencies**. Therapy is individualized based on severity, attack frequency, and patient preference.

On‑demand (abortive) therapy

• C1‑INH concentrate (plasma‑derived or recombinant): 20 U/kg IV (Berinert®, Cinryze®, Ruconest®). Works within 30–60 minutes.
• Icatibant (Firazyr®): A selective bradykinin B2‑receptor antagonist, 30 mg subcutaneously; repeat dose after 6 hours if needed.
• Ecallantide (Kalbitor®): A plasma kallikrein inhibitor, 30 mg SC; administered by a healthcare professional.
• Intravenous fresh frozen plasma (FFP) may be used when specific agents are unavailable, but it can worsen attacks in some patients.

Short‑term prophylaxis

Given before a known trigger (e.g., dental surgery).

• IV C1‑INH 10–20 U/kg 1–2 hours before the procedure.
• High‑dose oral tranexamic acid (1–1.5 g three times daily) for 2‑3 days around the event (less effective than C1‑INH).

Long‑term prophylaxis

• Lanadelumab (Takhzyro®): Monoclonal antibody against plasma kallikrein, 300 mg SC every 2 weeks (can be extended to 4 weeks).
• Berotralstat (Orladeyo®): Oral plasma kallikrein inhibitor, 150 mg once daily.
• Attenuated androgens (danazol, stanozolol): Effective but associated with liver toxicity, lipid changes, and virilization; used only when newer agents are unavailable.
• Regular IV C1‑INH prophylaxis (e.g., 60 U/kg twice weekly) is an option for patients who cannot tolerate newer agents.

Lifestyle and trigger avoidance

• Stop ACE inhibitors or ARBs if they are the precipitating factor.
• Limit estrogen‑containing medications (birth control, hormone replacement) when possible.
• Stay well‑hydrated and manage stress—both are reported triggers.
• Carry an emergency “treatment kit” (C1‑INH, icatibant, or other prescribed rescue medication) at all times.

Living with Kallikrein‑Kinin System Disorder

Effective self‑management empowers patients to reduce attack frequency and maintain quality of life.

• Education: Understand your specific subtype, typical triggers, and when to use rescue medication.
• Action plan: Write a clear, step‑by‑step plan (e.g., “If swelling starts, give icatibant 30 mg SC, call my nurse, go to ER if airway symptoms”). Keep it on your phone and fridge.
• Regular follow‑up: Annual visits with an immunologist or allergist to monitor C1‑INH levels, adjust prophylaxis, and discuss new therapies.
• Support networks: Join patient groups such as the HAE International community for emotional support and up‑to‑date information.
• Insurance & medication access: Work with a case manager to ensure coverage for biologics, which can be costly.

Prevention

While the underlying genetic defect cannot be changed, many modifiable factors can lower attack risk.

• Discontinue ACE inhibitors, neprilysin inhibitors, and any medications known to increase bradykinin.
• Use non‑estrogenic contraceptives (e.g., copper IUD, progestin‑only pills) if estrogen worsens symptoms.
• Avoid known physical triggers: dental procedures without prophylaxis, trauma to the face, extreme temperature changes.
• Maintain a healthy weight and manage hypertension, as obesity can exacerbate edema.
• Adopt stress‑reduction techniques (mindfulness, yoga, counseling).

Complications

If attacks are not promptly treated, serious complications can arise.

• Airway obstruction: Laryngeal edema can lead to asphyxiation; it is the leading cause of death in HAE.
• Intestinal ischemia: Severe abdominal edema may cause bowel obstruction or perforation.
• Psychological impact: Chronic unpredictability can cause anxiety, depression, and reduced work productivity.
• Medication side effects: Long‑term androgen use can cause liver adenomas, hypertension, and lipid abnormalities.

When to Seek Emergency Care

References

• Mayo Clinic. “Hereditary Angioedema.” https://www.mayoclinic.org (accessed 2024).
• Cleveland Clinic. “Kallikrein‑Kinin System and Angioedema.” https://my.clevelandclinic.org (2023).
• World Health Organization. “Rare Diseases: Hereditary Angioedema.” WHO Fact Sheet, 2022.
• National Institute of Allergy and Infectious Diseases. “Clinical Guidelines for the Management of Hereditary Angioedema.” NIH, 2021.
• Griffin, D. et al. “Long‑term prophylaxis with lanadelumab in hereditary angioedema.” New England Journal of Medicine 2020;383: 362‑372.
• Schmidt, Q. et al. “Icatibant for acute attacks of hereditary angioedema.” The Lancet 2019;393: 2029‑2036.